Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis - Full Text View

Purpose

RATIONALE: Endoscopic surgery is a less invasive type of surgery for laryngeal cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether endoscopic surgery is more effective than radiation therapy in treating laryngeal cancer of the glottis.

PURPOSE: This randomized phase II trial is studying endoscopic surgery to see how well it works compared with radiation therapy in treating patients with stage 0, stage I, or stage II laryngeal cancer of the glottis.

Condition	Intervention	Phase
Head and Neck Cancer	Procedure: endoscopic surgery Procedure: laser surgery Procedure: radiation therapy	Phase II

MedlinePlus related topics:

Cancer Endoscopy Head and Neck Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Active Control

Official Title:	Early Stage Glottic Cancer: Endoscopic Excision or Radiotherapy [EaStER]

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Feasibility [ Designated as safety issue: No ]
Patient acceptability [ Designated as safety issue: No ]

Secondary Outcome Measures:

Voice analysis [ Designated as safety issue: No ]
Quality of life [ Designated as safety issue: No ]
Economic assessment [ Designated as safety issue: No ]

Estimated Enrollment:	50
Study Start Date:	September 2005

Detailed Description:

OBJECTIVES:

Determine the feasibility of conducting a large phase III randomized study in the future, comparing radiotherapy vs endoscopic excision in patients with stage 0-II laryngeal cancer of the glottis.
Determine patient acceptability of the proposed trial design.
Compare the effect of using dedicated head and neck research nurses vs general nurses on patient recruitment.
Refine outcome measures, including voice analysis and quality of life.

OUTLINE: This is a randomized, controlled, multicenter, pilot study. Patients are stratified according to participating center and T stage (Tis or T1 vs T2a). Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients undergo endoscopic excision via CO_2 laser or cold steel.
Arm II: Patients undergo radiotherapy once daily, 5 days a week, for 3-4 weeks. Patients undergo vocal analysis at baseline and at 6 months and 1 and 2 years after randomization.

Quality of life is assessed at baseline, at 1 year, and then annually for 5 years.

After completion of study treatment, patients are followed periodically for up to 5 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed squamous cell carcinoma of the glottic larynx, including tumors at the anterior commissure
- Stage 0-II (Tis, T1, or T2a)
No clinical or radiological sign of nodal involvement
No evidence of distant metastases
Airway anatomy suitable for endoscopic excision

PATIENT CHARACTERISTICS:

Fit to receive radical treatment as either radiotherapy or endoscopic excision
Life expectancy ≥ 2 years
No other cancer in the past 10 years except basal cell carcinoma of the skin or adequately treated carcinoma in situ of the uterine cervix
No vasculitic conditions adversely affecting radiotherapy
No other co-existing medical condition that would limit life expectancy
Not pregnant

PRIOR CONCURRENT THERAPY:

No concurrent chemotherapy
No concurrent palliative treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00334997

Locations


United Kingdom, England
	Aintree University Hospital	Recruiting
	Liverpool, England, United Kingdom, L9 7AL
	Contact: Terry Jones, MD 44-151-529-5248 t.m.jones@liverpool.ac.uk
	Clatterbridge Centre for Oncology	Recruiting
	Merseyside, England, United Kingdom, CH63 4JY
	Contact: David J. Husband, MD 44-151-334-1155 david.husband@ccotrust.nhs.uk
	James Cook University Hospital	Recruiting
	Middlesbrough, England, United Kingdom, TS4 3BW
	Contact: Richard Wight, MD 44-16-4285-4023
	Norfolk and Norwich University Hospital	Recruiting
	Norwich, England, United Kingdom, NR4 7UY
	Contact: Paul Montgomery, MD 44-160-328-7286
	Southmead Hospital	Recruiting
	Bristol, England, United Kingdom, BS10 5NB
	Contact: Paul Tierney, MD 44-117-950-5050

United Kingdom, Scotland
	Royal Infirmary - Castle	Recruiting
	Glasgow, Scotland, United Kingdom, G4 0SF
	Contact: Kenneth Mackenzie, MD 44-141-232-0705

Sponsors and Collaborators

University College London Hospitals

Investigators


Study Chair:	Martin A. Birchall, MD	Southmead Hospital

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000478790, CRUK-BRD/05/024, EU-20611, CRUK-EASTER, ISRCTN17541410
First Received:	June 7, 2006
Last Updated:	July 23, 2008
ClinicalTrials.gov Identifier:	NCT00334997
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

stage I squamous cell carcinoma of the larynx

stage II squamous cell carcinoma of the larynx

stage 0 laryngeal cancer

Study placed in the following topic categories:

Epidermoid carcinoma

Otorhinolaryngologic Diseases

Otorhinolaryngologic Neoplasms

Respiratory Tract Diseases

Squamous cell carcinoma

Head and Neck Neoplasms

Carcinoma, squamous cell

Laryngeal carcinoma

Laryngeal Neoplasms

Laryngeal Diseases

Carcinoma, Squamous Cell

Carcinoma

Additional relevant MeSH terms:

Respiratory Tract Neoplasms

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on October 14, 2008

Sponsored by:	University College London Hospitals
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00334997